Clinical Trials Management Services, LLC | Clinical Trials Management Services, LLC

Research site

Location

223 E. Thousand Oaks Blvd., Suite 214, Thousand Oaks, California, United States of America

Site insights

Top conditions

Top treatments

S-217622

SAR443765

Efavaleukin Alfa

Dupilumab

Lanifibranor

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Teresa Tocher

Verified by this site

Active trials

6 of 9 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting

Cytomegalovirus Infection

Biological: mRNA-1647

Biological: Placebo

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficac...

Enrolling

Colitis Ulcerative

Drug: Placebo

Drug: Dupilumab

Comparative Efficacy, Safety, PK, and Immunogenicity Study

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy,...

Active, not recruiting

Osteoporosis, Postmenopausal

Biological: Denosumab

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (AIRCULES)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Active, not recruiting

Asthma

Drug: Placebo

Drug: Lunsekimig

VE303 for Prevention of Recurrent Clostridioides Difficile Infection (RESTORATiVE303)

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week...

Enrolling

CDI

C.Difficile Diarrhea

Biological: Placebo

Biological: VE303

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms